# A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity

> **NCT07478822** · PHASE3 · RECRUITING · sponsor: **Chongqing Claruvis Pharmaceutical Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Upper Limb Spasticity

## Interventions

- **BIOLOGICAL:** Recombinant botulinum toxin type A for injection (YY001)

## Key facts

- **NCT ID:** NCT07478822
- **Lead sponsor:** Chongqing Claruvis Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-27
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07478822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07478822, "A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07478822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*